Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
ATAI Life Sciences N.V. (Name of Issuer) |
Common Shares (Title of Class of Securities) |
45822R101 (CUSIP Number) |
Evan S. Simpson 1 New Fetter Lane, London, X0, EC4A 1AN 44 20 795984-26 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
06/02/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.


The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
CUSIP No. | 45822R101 |
1 |
Name of reporting person
Apeiron Investment Group Ltd. | ||||||||
2 | Check the appropriate box if a member of a Group (See Instructions)
![]() ![]() | ||||||||
3 | SEC use only | ||||||||
4 |
Source of funds (See Instructions)
WC, OO | ||||||||
5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
![]() | ||||||||
6 | Citizenship or place of organization
MALTA
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
11 | Aggregate amount beneficially owned by each reporting person
46,521,717.00 | ||||||||
12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
![]() | ||||||||
13 | Percent of class represented by amount in Row (11)
22.1 % | ||||||||
14 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13D
|
CUSIP No. | 45822R101 |
1 |
Name of reporting person
Apeiron Presight Capital Fund II, L.P. | ||||||||
2 | Check the appropriate box if a member of a Group (See Instructions)
![]() ![]() | ||||||||
3 | SEC use only | ||||||||
4 |
Source of funds (See Instructions)
AF | ||||||||
5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
![]() | ||||||||
6 | Citizenship or place of organization
DELAWARE
div> | ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
11 | Aggregate amount beneficially owned by each reporting person
1,799,302.00 | ||||||||
12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
![]() | ||||||||
13 | Percent of class represented by amount in Row (11)
0.9 % | ||||||||
14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
CUSIP No. | 45822R101 |
1 |
Name of reporting person
Presight Capital Management I, L.L.C. | ||||||||
2 | Check the appropriate box if a member of a Group (See Instructions)
![]() ![]() | ||||||||
3 | SEC use only | ||||||||
4 |
Source of funds (See Instructions)
| ||||||||
5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
![]() | ||||||||
6 | Citizenship or place of organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
11 | Aggregate amount beneficially owned by each reporting person
1,799,302.00 | ||||||||
12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
![]() | ||||||||
13 | Percent of class represented by amount in Row (11)
0.9 % | ||||||||
14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
CUSIP No. | 45822R101 |
1 |
Name of reporting person
Fabian Hansen | ||||||||
2 | Check the appropriate box if a member of a Group (See Instructions)
![]() ![]() | ||||||||
3 | SEC use only | ||||||||
4 |
Source of funds (See Instructions)
| ||||||||
5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
![]() | ||||||||
6 | Citizenship or place of organization
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
11 | Aggregate amount beneficially owned by each reporting person
1,799,302.00 | ||||||||
12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
![]() | ||||||||
13 | Percent of class represented by amount in Row (11)
0.9 % | ||||||||
14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
CUSIP No. | 45822R101 |
1 |
Name of reporting person
Christian Angermayer | ||||||||
2 | Check the appropriate box if a member of a Group (See Instructions)
![]() ![]() | ||||||||
3 | SEC use only | ||||||||
4 |
Source of funds (See Instructions)
| ||||||||
5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
![]() | ||||||||
6 | Citizenship or place of organization
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
11 | Aggregate amount beneficially owned by each reporting person
46,749,092.00 | ||||||||
12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
![]() | ||||||||
13 | Percent of class represented by amount in Row (11)
22.2 % | ||||||||
14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
Item 1. | Security and Issuer |
(a) | Title of Class of Securities:
Common Shares |
(b) | Name of Issuer:
ATAI Life Sciences N.V. |
(c) | Address of Issuer's Principal Executive Offices:
Wallstrasse 16, Berlin,
GERMANY
, 100179. |
Item 2. | Identity and Background |
(a) | This Amendment No. 1 (the "Amendment") to Schedule 13D amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission on February 24, 2025 (the "Schedule 13D"). This Amendment is filed by: (i) Apeiron Investment Group Ltd. ("Apeiron"); (ii) Apeiron Presight Capital Fund II, L.P. ("Presight II"); (iii) Presight Capital Management I, L.L.C. ("Presight Management"); (iv) Fabian Hansen; and (v) Christian Angermayer. |
(b) | The principal business address of Apeiron and Mr. Angermayer is 66 & 67 Amery Street, SLM1707, Sliema, Malta. The principal business address of each of the remaining Reporting Persons is 440 N Barranca Ave #3391, Covina, CA 91723 USA. |
(c) | The principal business of Apeiron and Presight II are making investments. The principal business of Presight Management is acting as the general partner of Presight II. Apeiron's sole director is Mario Frendo and his principal business address is 66 & 67 Amery Street, SLM1707, Sliema, Malta. His present principal occupation is Senior Legal Counsel at Apeiron. |
(d) | No |
(e) | No |
(f) | Presight II and Presight Management are organized under the laws of the state of Delaware. Apeiron is organized under the laws of the Malta. Each of Messrs. Hansen and Angermayer is a German citizen. Mr. Frendo is a Maltese citizen. |
Item 5. | Interest in Securities of the Issuer |
(a) | As of June 4, 2025, the Reporting Persons collectively beneficially own 46,521,717 Common Shares, representing approximately 22.1% of the voting rights attached to the Common Shares. |
(b) | The following sets forth, as of the date of this Amendment, the aggregate number of Ordinary Shares and percentage of Ordinary Shares beneficially owned by each of the Reporting Persons, as well as the number of Ordinary Shares as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 210,330,950 Common Shares outstanding as of June 3, 2025, comprising (i) the 200,337,609 Common Shares outstanding as of May 9, 2025, as reported by the Issuer in its Form 10-Q dated May 14, 2025 and (ii) the 9,993,341 Common Shares issued on June 3, 2025 in connection with an investment in the Issuer by two private investors (the "Pipe Investors"), as reported by the Issuer in its Form 8-K dated June 2, 2025. Sole Shared Sole power to Shared power power dispose power Amount to vote or to vote or to or to direct to dispose or beneficially Percent to direct direct the the to direct the Reporting Person owned of class the vote vote disposition disposition Apeiron Investment Group, Ltd. 46,521,717 22.1% 0 46,521,717 0 46,521,717 Apeiron Presight Capital Fund II, L.P. 1,799,302 0.9% 0 1,799,302 0 1,799,302 Presight Capital Management I, L.L.C. 1,799,302 0.9% 0 1,799,302 0 1,799,302 Fabian Hansen 1,799,302 0.9% 0 1,799,302 0 1,799,302 Christian Angermayer 46,749,092 22.2% 227375 46,521,717 227,375 46,521,717 Presight II is the record holder of 1,799,302 Common Shares. Apeiron is the record holder of 42,369,415 Common Shares and may be deemed to own an additional 2,353,000 Common Shares underlying convertible notes of the Issuer (the "Convertible Notes"). Christian Angermayer also holds 214,000 vested options that are each exercisable for $5.68 into one Common Share, and 13,375 additional stock options will vest and be exercisable on or about June 9, 2025. Presight Management is the general partner of Presight II. Apeiron and Fabian Hansen are the managing members of Presight Management. Christian Angermayer is the controlling shareholder of Apeiron. As a result, each of Presight Management, Apeiron, Mr. Hansen and Mr. Angermayer may be deemed to share beneficial ownership of the securities held by Presight II, and Mr. Angermayer may be deemed to share beneficial ownership of the securities held by Apeiron. |
(c) | Except as described in this Item 5, none of the Reporting Persons has beneficial ownership of any Common Shares or, except as described in this Schedule 13D, has effected any transaction in the Ordinary Shares during the past 60 days. |
(d) | No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares owned, directly or indirectly, by the Reporting Persons. |
(e) | N/A |
Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
Item 6 of the Schedule 13D is hereby amended and supplemented by the addition of the following: Voting Agreement On June 2, 2025, the Issuer, its directors and the members of the executive team of the Issuer, Beckley Psytech Limited and Apeiron entered into certain voting agreements in connection with the Acquisition. Pursuant to Apeiron's voting agreement with the Issuer (the "Voting Agreement"), Apeiron has agreed to vote (or cause to be voted) all of the Common Shares held by it in favor of certain matters set forth in the Voting Agreement, including to support (i) without limitation, shareholder approvals to approve the transactions contemplated by the share purchase agreement entered into in connection with the Acquisition and (ii) subject to certain conditions, any potential transaction that may be pursued by the Issuer to move the legal and tax domicile of the Issuer from the Netherlands (in respect of its corporate seat) and Germany (in respect of its tax domicile) to Delaware. The foregoing description of the Voting Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Voting Agreement, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Shareholders Rights Agreement On June 2, 2025, Apeiron entered into a shareholders rights agreement with the Issuer (the "Rights Agreement"). Under the Rights Agreement, Apeiron will have the right, subject to certain requirements, to select a number of director designees equal to (i) two, for so long as Apeiron and its affiliates beneficially own no less than 12.5% of the equity securities of the Issuer (inclusive of Common Shares issued or issuable in connection with the exercise of options, warrants, rights, units or other securities) and (ii) one, for so long as Apeiron and its affiliates collectively beneficially own at least 7.5% but less than 12.5% of such Issuer equity securities. Apeiron also entered into a lock-up agreement (the "Lock-Up Agreement") on June 2, 2025 containing customary lock-up terms, pursuant to which Apeiron will, subject to certain exceptions, not transfer any equity securities of the Issuer for a certain specified period. At the expiration of such period, the lock-up restrictions will fall away in part on a monthly basis until the date that is twelve months following the expiration of such period. The foregoing description of the Rights Agreement and the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Rights Agreement and the Lock-Up Agreement, copies of which are attached hereto as Exhibits 99.2 and 99.3, respectively, and are incorporated herein by reference. Registration Rights Agreement On June 2, 2025, the Issuer entered into a registration rights agreement with Apeiron, Mr. Angermayer and the PIPE Investors (the "Registration Rights Agreement") providing for certain registration rights with respect to Common Shares held by such holders from time to time. The Registration Rights Agreement requires the Issuer to file a registration statement under the Securities Act of 1933, as amended, providing for the resale of all or part of the registrable securities held by the parties thereto as promptly as practicable and use reasonable best efforts to cause such registration statement to be declared effective within the timelines specified therein, and thereafter to keep such registration statement effective for the periods specified therein. Apeiron will have customary demand rights that will require the Issuer to file registration statements registering its registrable securities. The Issuer has agreed to reasonably assist and cooperate, including by making management available for an electronic "road show" or other marketing efforts, in block trades and marketed or non-marketed underwritten shelf takedown offerings for sales by Apeiron with an offering price, in the aggregate, of at least $25 million. The Registration Rights Agreement also includes customary piggyback rights for Apeiron, subject to certain priority provisions. The Issuer has agreed to bear all registration expenses, including reasonable and documented fees of one counsel for all the selling shareholders, other than customary underwriting commissions or fees, regardless of whether a registration statement is filed or becomes effective. The Registration Rights Agreement also contains customary indemnity, exculpation and contribution obligations by the Issuer and the other parties to the Registration Rights Agreement. The foregoing description of the Registration Rights Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Registration Rights Agreement, a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference. Option Grants On June 2, 2025, the Issuer granted to Mr. Angermayer in further consideration of his continued service as a consultant and other valuable consideration (i) an option to purchase 337,686 ordinary shares of the Issuer that will vest with respect to 131,698 shares subject to the option based on the Issuer's standard four year vesting schedule and with respect to 205,988 shares subject to the option based on the Issuer achieving asset value goals by December 31, 2026, and (ii) an option to purchase 292,500 shares that will vest based on the Issuer's standard four year vesting schedule. In addition, the options are subject to Mr. Angermayer entering into an amended consultancy agreement that provides for compliance with the Issuer's code of conduct, compliance program and the Voting Agreement. Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer. | |
Item 7. | Material to be Filed as Exhibits. |
Exhibit NoDescription 99.1 Voting Agreement, dated June 2, 2025, between Apeiron, the Issuer and Beckley Psytech Limited (incorporated by reference to Exhibit 10.2 to Form 8-K filed by the Issuer on June 2, 2025) 99.2 Shareholders Rights Agreement, dated June 2, 2025, between Apeiron and the Issuer (incorporated by reference to Exhibit 10.3 to Form 8-K filed by the Issuer on June 2, 2025) 99.3 Lock-Up Agreement, dated June 2, 2025, between Apeiron and the Issuer (incorporated by reference to Exhibit 10.4 to Form 8-K filed by the Issuer on June 2, 2025) 99.4 Registration Rights Agreement, dated June 2, 2025, between Apeiron, Christian Angermayer, the Issuer and certain shareholders named therein (incorporated by reference to Exhibit 10.8 to Form 8-K filed by the Issuer on June 2, 2025) |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
Signature: | /s/ Christian Angermayer | Name/Title: | Christian Angermayer | Date: | 06/04/2025 | |